Search research articles
Contact Us
Filters
Showing results (491-500 of 501) with videos related to
Page
of 51
Sort By:
JAMA Oncology
|
September 17, 2020
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial
Srikala S Sridhar, Normand Blais, Ben Tran, et al.
European Urology
|
November 5, 2013
The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium
Fabio A B Schutz, Wanling Xie, Frede Donskov, et al.
European Urology Oncology
|
August 15, 2019
Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Jeffrey Graham, J Connor Wells, Frede Donskov, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 22, 2025
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)
H-M Lin, T Scheinberg, N Portman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2021
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial
M Annala, S Fu, J V W Bacon, et al.
The Lancet. Oncology
|
March 29, 2023
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
Christopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
The New England Journal of Medicine
|
June 4, 2019
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D Davis, Andrew J Martin, Martin R Stockler, et al.
European Urology
|
May 25, 2021
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
Christopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
European Urology Oncology
|
February 3, 2026
Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304)
Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2021
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP
Martin R Stockler, Andrew J Martin, Ian D Davis, et al.
Page
of 51
Search research articles
Search
Showing results (491-500 of 501) with videos related to
Sort By:
Page
of 51
JAMA Oncology
|
September 17, 2020
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial
Srikala S Sridhar, Normand Blais, Ben Tran, et al.
European Urology
|
November 5, 2013
The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium
Fabio A B Schutz, Wanling Xie, Frede Donskov, et al.
European Urology Oncology
|
August 15, 2019
Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Jeffrey Graham, J Connor Wells, Frede Donskov, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 22, 2025
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)
H-M Lin, T Scheinberg, N Portman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2021
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial
M Annala, S Fu, J V W Bacon, et al.
The Lancet. Oncology
|
March 29, 2023
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
Christopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
The New England Journal of Medicine
|
June 4, 2019
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D Davis, Andrew J Martin, Martin R Stockler, et al.
European Urology
|
May 25, 2021
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy
Christopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
European Urology Oncology
|
February 3, 2026
Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304)
Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2021
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP
Martin R Stockler, Andrew J Martin, Ian D Davis, et al.
Page
of 51